

## Product Information

### Tissue Inhibitor of Metalloproteinase-2 (TIMP-2)

from BHK cells transfected with mouse TIMP-2

Product Number **T8447**

#### Product Description

Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) is purified by substrate-affinity chromatography from BHK (baby hamster kidney) cells transfected with full-length mouse TIMP-2. It is essentially free of matrix metalloproteinases and other known TIMPs.

Mouse TIMP-2 can be used as a positive control in enzymatic assays, ELISA assays, immunoblotting, and substrate gel analysis (reverse zymograms). TIMP-2 is largely unglycosylated with a molecular mass of approximately 22 kDa by immunoblotting run under reducing conditions.

The matrix metalloproteinases (MMPs) are a family of at least eighteen secreted and membrane-bound zinc-endopeptidases. Collectively, these enzymes can degrade all the components of the extracellular matrix (ECM), including fibrillar and non-fibrillar collagens, fibronectin, laminin and basement membrane glycoproteins. In general, a signal peptide, a propeptide, and a catalytic domain containing the highly conserved zinc-binding site characterizes the structure of the MMPs. In addition, fibronectin-like repeats, a hinge region, and a carboxyl-terminal hemopexin-like domain allow categorization of MMPs into the collagenase, gelatinase, stromelysin and membrane-type MMP subfamilies.<sup>1-3</sup> MMPs contain the motif His-Glu-X-X-His (X represents any amino acid) that binds zinc in the catalytic site, as well as another zinc molecule and two calcium molecules structurally. They fall within the matrixin subfamily with the EC designation 3.4.24.x. This group also includes astacin, reprolysin, and serralyisin, as well as other more divergent metalloproteinases. All MMPs are synthesized as proenzymes, and most of them are secreted from the cells as proenzymes. Thus, the activation of these proenzymes is a critical step that leads to extracellular matrix breakdown.

MMPs play an important role in wound healing, apoptosis, bone elongation, embryo development, uterine involution, angiogenesis,<sup>4</sup> and tissue remodeling, and in diseases such as multiple sclerosis,<sup>2,5</sup> Alzheimer's,<sup>2</sup> malignant gliomas,<sup>2</sup> lupus, arthritis, periodontitis, glomerulonephritis, atherosclerosis, tissue ulceration, and in cancer cell invasion and metastasis.<sup>6</sup>

Numerous studies have shown that there is a close association between expression of various members of the MMP family by tumors and their proliferative and invasive behavior and metastatic potential.

The tissue inhibitors of metalloproteinases (TIMPs) are naturally-occurring proteins that specifically inhibit matrix metalloproteinases and regulate extracellular matrix turnover and tissue remodeling by forming tightly bound inhibitory complexes with the MMPs. Thus, TIMPs maintain the balance between matrix destruction and formation. An imbalance between MMPs and the associated TIMPs may play a significant role in the invasive phenotype of malignant tumors.

TIMP proteins share several structural features including six loops held in place by six disulfide bonds arranged in three knotlike structures. The 12 cysteine residues that form these six disulfide bonds are located in conserved regions of the molecule and are essential for the formation of native conformations. The amino-terminal region is necessary for inhibitory activities and contains a consensus sequence (VIRAK). Each TIMP is translated with a 29 amino acid leader sequence that is cleaved to produce the mature protein. The carboxyl-terminal regions are divergent, which may enhance the selectivity of inhibition and binding efficiency. Although the TIMP proteins share high homology, they may either be secreted extracellularly in soluble form (TIMP-1, TIMP-2, and TIMP-4) or bind to extracellular matrix components (TIMP-3).

The MMPs and TIMPs can be divided into two groups with respect to gene expression: the majority exhibit inducible expression and a small number are produced constitutively or are expressed at very low levels and are not inducible. Among agents that induce MMP and TIMP production are the inflammatory cytokines TNF- $\alpha$  and IL-1 $\beta$ . A marked cell type specificity is a hallmark of both MMP and TIMP gene expression (i.e., only a limited number of cell types can be induced to make these proteins).

Mouse Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) has been described by two groups.<sup>7,8</sup> The predicted murine TIMP-2 amino acid sequence shows 96% identity with human TIMP-2.<sup>9</sup> This high degree of homology between the mouse and human TIMP-2 proteins suggests that TIMP-2 performs an essential biological function.<sup>9</sup> Murine TIMP-2 shows only 42% identity with murine TIMP-1.

TIMP-2 inhibits the active forms of MMP-2 and also complexes with the proform of MMP-2.<sup>10</sup> Like MMP-2, TIMP-2 shows little inducibility, and its message levels are unaffected by TGF- $\beta$ , IL-1, or TNF- $\alpha$ . TIMP-2, an efficient inhibitor of MMP-2, is required at low concentrations for the activation of MMP-2. It is thought that MMP-2 is activated by a membrane-bound MMP; and that TIMP-2 is required to bring the MMP-2 to the cell surface.

TIMP-2 is constitutively produced and secreted in a soluble form by most cell types, with major sites in the lung and liver.

#### Reagent

The product is supplied in 0.01 M phosphate buffered saline, pH 7.4, containing 150 mM sodium chloride, and 50% glycerol (v/v). The protein concentration is approximately 100  $\mu$ g/ml.

#### Storage/Stability

Store at -20 °C. Do not store below -20 °C.

#### Product Profile

Purity: >95% as determined by SDS-PAGE, visualized by silver stain.

Note: TIMP-2 is constitutively produced in low (pg/ml) levels in most cell types in tissue culture. The low protein levels produced often require concentration of the cell culture media to visualize the bands by immunoblotting.

#### References

1. Borkakoti, N., Matrix metalloproteases: variations on a theme. *Prog. Biophys. Mol. Biol.*, **70**, 73-94 (1998).
2. Yong, V.W., et al., Matrix metalloproteinases and diseases of the CNS. *Tr. Neuro.*, **21**, 75-80 (1998).
3. Kähäri, V.M., and Saarialho-Kere, U., Matrix metalloproteinases in skin. *Exp. Dermatol.*, **6**, 199-213 (1997).
4. Halpert, I., et al., Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. *Proc. Natl. Acad. Sci., USA*, **93**, 9748-9753 (1996).
5. Chandler, S., et al., Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. *J. Neuroimmunol.*, **72**, 155-161 (1997).
6. Birkedal-Hansen, H., et al., Matrix metalloproteinases: a review. *Crit. Rev. Oral. Biol. Med.*, **4**, 197-250 (1993).
7. Kishi, J., et al., Purification and characterization of a new tissue inhibitor of metalloproteinases (TIMP-2) from mouse colon 26 tumor cells. *Matrix*, **11**, 10-16 (1991).
8. Shimizu, S., et al., Cloning and sequencing of the cDNA encoding a mouse tissue inhibitor of metalloproteinase-2. *Gene*, **114**, 291-292 (1992).
9. Leco, K.J., et al., Differential regulation of TIMP-1 and TIMP-2 mRNA expression in normal and Ha-ras-transformed murine fibroblasts. *Gene*, **117**, 209-217 (1992).
10. Stetler-Stevenson, W.G., et al., Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. *J. Biol. Chem.*, **264**, 17374 (1989).

kaa 02/05

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.